

Listing of countries in which pathogen reduction technology systems and products are in use

Country	INTERCEPT Blood System ^a		Mirasol PRT ^b		Theraflex		Octoplas
	Platelets	Plasma	Platelets	Plasma	Platelets ^c	Plasma ^d	Plasma
Australia							X
Austria	X		X			X	X
Azerbaijan							X
Bahrain							X
Belarus			X	X		X	
Belgium	X	X	X			X	X
Canada							X
Chile	X	X					
Czech Republic	X		X	X			X
Egypt			X				
Finland							X
France	X	X					
Germany		X				X	X
Greece	X	X	X	X		X	
Hong Kong						X	
Hungary							X
Ireland, Republic of							X
Italy	X	X	X	X		X	X
Kazakhstan	X	X	X	X		X	
Kuwait	X						X
Libya			X				
Lithuania			X				
Luxemburg			X				X
Malaysia	X					X	X
Malta							X
Mexico							X
The Netherlands							X
New Zealand							X
Norway	X		X				X
Oman							X
Poland			X	X		X	
Portugal	X						X
Qatar			X	X			X
Romania							X
Russia	X	X	X	X		X	
Saudi Arabia	X						X
Serbia			X	X			
Singapore						X	
Slovakia							X

Slovenia	X						
Spain	X	X	X	X		X	
Sweden	X						X
Switzerland	X						X
Turkey	X	X					
Ukraine	X	X				X	
United Arab Emirates	X	X					X
United Kingdom						X	X
United States of America	X	X					X
Yemen			X	X			X

Footnotes:

^aApproved Indication for Use (exUSA): The INTERCEPT Blood System is intended to inactivate a broad spectrum of viruses, bacteria, and parasites as well as contaminating donor leukocytes in platelet components. INTERCEPT treatment may be used as an alternative to gamma irradiation for prevention of transfusion-associated graft-versus-host disease (TA-GVHD). INTERCEPT treatment may be used in place of cytomegalovirus (CMV) testing and leukoreduction for prevention of transfusion-transmitted CMV infection

Approved Indication for Use (USA): The INTERCEPT Blood System is intended to inactivate a broad spectrum of viruses, bacteria, and parasites as well as contaminating donor leukocytes in platelet components, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-GVHD).

^bApproved Intended Use: The Mirasol Pathogen Reduction System is intended to reduce the pathogen load and inactivate residual white blood cells in donor platelet concentrates or plasma for transfusion. Mirasol system treatment can be used instead of gamma irradiation to prevent transfusion-associated graft-versus-host disease (TA-GVHD). Mirasol system treatment in combination with leukoreduction can be used instead of cytomegalovirus (CMV) testing to prevent transfusion-transmitted CMV infection.

^cThe THERAFLEX UV-Platelets system is currently under further clinical evaluation and so is not in routine use.

CE Mark – Approved Intended Use: The THERAFLEX UV-Platelets system is intended to inactivate bacteria, viruses, parasites and residual donor leucocytes (white blood cells) in both apheresis and buffy-coat derived platelet concentrates. The system can be used to replace gamma irradiation to prevent transfusion-associated graft-versus-host disease (TA-GVHD).

^dApproved Intended Use: The THERAFLEX MB-Plasma System is intended to inactivate viruses and parasites. It is a user-friendly in-house treatment for single units of plasma. The GMP-conforming procedure is adapted for the inactivation of FFP from apheresis or whole blood plasma. The MB-Plasma System uses a combination of a membrane filter Plasmaflex PLAS4, (which removes residual leucocytes, red cells, platelets and aggregates, intra-cellular viruses and minimizes the amount of microvesicles and microparticles), a dry Methylene Blue pill, visible light and a Blueflex Methylene Blue removal filter.